If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
Those who invested in Pfizer three years ago and hung on are not thrilled.
They would have done much better with a simple S&P 500 index fund.
Still, Pfizer today offers a fat dividend and plenty of growth potential.
10 stocks we like better than Pfizer ›
Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (NYSE: PFE) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in Pfizer on Aug. 8, 2022, hung on and reinvested dividends, that sum would have been worth $585 on Aug. 8, 2025. Ouch!
For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of roughly 17% per year, turning $1,000 into $1,615.
Here's some good news, though: Stock investors need to look forward much more than backward. Trailing returns are in the past. What matters most for current Pfizer investors and would-be Pfizer investors is how the company will perform from here on. And Pfizer's future is looking promising.
Some investors have been disappointed in Pfizer when they've compared recent results to those from the past. But those past years were exceptional boom years thanks to Pfizer's COVID-19 vaccine and Paxlovid COVID-19 treatment. Those were in great demand, but demand has fallen. Others worry because some of Pfizer's big sellers, such as Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi, and Vyndaqel, are coming off patent protection in the next few years. Pfizer has been planning for that, and investing in its pipeline, which features more than 100 active programs -- many of which are in oncology. Pfizer has also been getting additional approvals for its drugs, and it has been cutting its costs in an effort to boost profitability.
Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 11, 2025
Selena Maranjian has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Kodak warns it might not continue in business. Here's why.
Kodak is warning that its future in business is looking very blurry. The iconic 133-year-old business cautioned Monday that there's "substantial doubt" about its ability to continue as a going concern because it might not have the financial resources to meet its future debt obligations, according to an Aug. 11 regulatory filing. A so-called going concern warning is an accounting term that signals a risk that a business might cease operations. Shares of Kodak plunged $1.73, or 26%, to $5.05 in Tuesday morning trading. Reached for comment, a Kodak spokesperson pointed to the statement in its regulatory filing. The warning is the latest development in the photography company's storied history, which includes introducing one of the first consumer cameras in the 1880s and mass manufacturing film rolls for hobbyists and professionals alike. But Kodak struggled to adapt when digital cameras overtook film starting in the 1990s, leading to a bankruptcy filing in 2012. Its current financial crunch is tied to almost $500 million in short-term debt obligations, as well as more than $200 million in pension liabilities. Last year, Kodak had said it would end its pension plan in order to reduce debt, according to the Wall Street Journal. Kodak should have "a clear understanding by Aug.15 of how we will satisfy our obligations to all plan participants," Chief Financial Officer David Bullwinkle said in a statement, referring to the pension plan. A Kodak moment Rochester, New York-based Eastman Kodak, founded by inventor George Eastman in 1892, mass produced the famed Brownie and Instamatic cameras, popularizing photography as a pastime for generations of Americans. Its yellow-and-red film boxes were ubiquitous in photo shops and other retailers. Eastman said his goal was "to make the camera as convenient as the pencil," according to the Kodak website. But Kodak faced competition from Japanese companies, including Fujifilm in the 1990s, as well as the shift to digital technology, leading to its filing for bankruptcy protection in 2012. The company wound up selling off many of its businesses and patents, while shutting down the camera manufacturing unit that first made it famous. It received approval for its plan to emerge from court oversight a year later. At the time, Kodak was looking to recreate itself as a new, much smaller company focused on commercial and packaging printing. Kodak is now nearing completion on a manufacturing plant to create regulated pharmaceutical products. The company already makes unregulated key starting materials for pharmaceuticals. Production at the retrofitted facility is expected to start later this year. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Trump says he's placing D.C. police under federal control, deploying National Guard Could Tropical Storm Erin become the first Atlantic hurricane of 2025?
Yahoo
12 minutes ago
- Yahoo
Bath & Body Works opens kiosks in 600 college bookstores. See list.
It's back to school for Bath & Body Works as the company announced plans to sell its products in over 600 college campus stores for the 2025-2026 academic year. The brand's reach aims to strengthen its connection with Generation Z consumers after being named the No. 1 fragrance brand for American teens and the third overall most-shopped at beauty stores by teens in the Piper Sandler Taking Stock with Teens Spring 2025 Survey. Bath & Body Works has partnered with ICM Distributing Company to launch kiosks, working with national chains such as Barnes & Noble College and Follett-operated bookstores, as well as independent campus retailers, according to Chief Merchandising Officer Betsy Schumacher. What products will be available at college campuses? A variety of Bath & Body Works products will be available on college campuses, including body creams and lotions, fragrance mists, Wallflower diffusers, PocketBac hand sanitizers, lip products such as glosses and scrubs, hand soap and 3-wick candles, Schumacher said. Scents like Champagne Toast, Mahogany Teakwood and Clean House Vibes are standout scents and will be available in these bookstores, added Schumacher. What campuses will Bath & Body Works be available at? Bath & Body Works kiosks will be located on approximately 600 college campuses nationwide. The following 400-plus locations are at Barnes & Noble College- and Follett-owned campus bookstores, provided to USA TODAY by Bath & Body Works. The remaining locations, not included in the chart below, are independently owned bookstores. Can't see the chart in your browser? Visit Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@ This article originally appeared on USA TODAY: Bath & Body Works opens kiosks in 600 college bookstores. See list.
Yahoo
12 minutes ago
- Yahoo
Tesla To Open Austin Robotaxi Service In September
Tesla (NASDAQ:TSLA) is set to open its Austin robotaxi service to the public in September, CEO Elon Musk announced on social media. The move follows an invite-only phase that began in June with a small fleet of driverless cars and a limited user base. Warning! GuruFocus has detected 5 Warning Signs with RIVN. The company has locked in all the necessary permits to operate statewide in Texas, with approval from the Texas Department of Licensing and Regulation. It will run as a licensed Transportation Network Company through August 2026. Guggenheim's Ronald Jewsikow called the timing earlier than expected and a sign Tesla is confident in both the tech and the feedback from early riders. He said the expanded full self-driving model could bolster the bull case for Tesla's fleet eventually transitioning into robotaxis. While safety drivers will still be in place and no date has been given for their removal, he doesn't see that dampening investor enthusiasm. Tesla shares have climbed 7.5% in the past six weeks but remain more than 30% below their 52-week high. The EV maker's market cap sits at $1.09T, ranking it the 10th largest U.S. company. This article first appeared on GuruFocus.
